Comparison of depression risk and depression-related ambulatory care utilization in sarcopenia patients with and without Chinese herbal medicine

比较服用和未服用中药的肌少症患者的抑郁风险和抑郁相关门诊就诊情况

阅读:2

Abstract

BACKGROUND: The impact of psychiatric disorder, especially depression, on the prognosis of sarcopenic patients is gaining prominence. Yet, there have been very few studies focusing on this issue, let alone the related targeted mental health prevention. This cohort-based nested case-control study is geared to compare risk of depression and the depression-related ambulatory care utilization for sarcopenia persons with and without receiving add-on Chinese herbal medicines (CHMs) treatment. AIM: To compare risk of depression and the depression-related ambulatory care utilization for sarcopenia persons with and without receiving add-on CHMs treatment. METHODS: In the beginning, we recruited those aged 20-70 years with newly diagnosed sarcopenia and free of depression between 2002 and 2010 from a nationwide insurance database. From them, we identified cases with depression onset occurring after sarcopenia until December 31, 2013. To cautiously isolate the effect of CHMs, we established the matched sets of treated and untreated subjects with CHMs use by randomly frequency matching. A conditional logistic regression was executed to explore the association of CHMs to depression risk, and the frequency and costs of depression-related ambulatory care were compared using Mann-Whitney U test. RESULTS: Addition of CHMs to routine care of sarcopenia notably correlated with a lower risk of depression. A remarkable effect of CHMs in reducing depression was detected when sarcopenia subjects received CHMs for more than three years, lowering depression risk by as much as 65%. As compared to CHMs users, the non-CHMs users indeed incurred higher frequency and costs of depression-related ambulatory care after depression attack (P < 0.05). Notably, the costs for per depression-related ambulatory care profoundly increased with the years after depression attack. CONCLUSION: Sarcopenic patients can greatly benefit from add-on CHMs treatment, underscoring the urgent need for interdisciplinary collaboration and proactive treatment planning.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。